⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclooctane SCHEMBL27993947 | 0.92 | — | — | |
| SCHEMBL28215901 | 0.83 | — | — | |
| SCHEMBL28823536 | 0.80 | — | — | |
| SCHEMBL223402 | 0.71 | — | — | |
| SCHEMBL7366717 | 0.63 | — | — | |
| SCHEMBL12079523 | 0.63 | — | — | |
| SCHEMBL12079525 | 0.63 | — | — | |
| SCHEMBL31645514 | 0.60 | — | — | |
| SCHEMBL708361 | 0.58 | — | — | |
| SCHEMBL18320895 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 391 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| EP-4441811-A1 | CATHOLYTES FOR A SOLID-STATE BATTERY | QuantumScape Battery, Inc. (US) | 2024-10-09 | — | — | EP | claimed |
| CN-118318325-A | Catholyte for solid state battery | 昆腾斯科普电池公司 | 2024-07-09 | — | — | CN | claimed |
| WO-2024077078-A2 | STERYLGLUCOSIDASE INHIBITING COMPOSITIONS AND METHOD OF USING | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-04-11 | — | — | WO | claimed |
| CN-116422109-A | Self-extraction layered carbon dioxide trapping system and method | 嘉兴市碳捕手科技有限责任公司 | 2023-07-14 | — | — | CN | claimed |
| WO-2023121838-A1 | CATHOLYTES FOR A SOLID-STATE BATTERY | QUANTUMSCAPE BATTERY, INC. (US) | 2023-06-29 | — | — | WO | claimed |
| EP-4126229-A1 | MTORC1 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2021195599-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | claimed |
| CN-107501275-B | It can be used as the compound of ATR kinase inhibitor | Votex Pharmaceutical Co., Ltd. (US) | 2019-11-22 | — | — | CN | claimed |
| CN-104411311-A | Substituted benzamides and their use | UNIV LELAND STANFORD JUNIOR | 2015-03-11 | — | — | CN | claimed |
| WO-2010109475-A1 | A SUSTAINED RELEASE ORAL COMPOSITION OF AN ANTIPSYCHOTIC AGENT | GENEPHARM INDIA PRIVATE LIMITED (IN) | 2010-09-30 | — | — | WO | claimed |
| EP-1865962-A2 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | Arcadia Pharmaceuticals Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006107948-A9 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | ACADIA PHARM INC (US) | 2007-02-22 | — | — | WO | claimed |
| WO-2006107948-A2 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| WO-1999011612-A2 | SUBSTITUTED CYCLIC COMPOUNDS AND MIXTURES COMPRISING SAME | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-11 | — | — | WO | claimed |
| CN-1171403-A | 4 -thia -1 -azabicyclo [3. 2. 0] heptane -3 -imino -2 -isopropylidene -7 -oxo analogons of beta -lactams, processes for their preparation and use thereof | PLIVA PHARM & CHEM WORKS (HR) | 1998-01-28 | — | — | CN | claimed |
| US-5684217-A | Process for preparing 3-fluoro-4,6-dichlorotoluene | BAYER AKTIENGESELLSCHAFT (DE) | 1997-11-04 | — | — | US | claimed |
| EP-0161801-B1 | PERHYDROTHIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANKYO COMPANY LIMITED (JP) | 1990-11-07 | — | — | EP | claimed |
| WO-1984002704-A2 | TETRACYCLIC COMPOUNDS | BEECHAM GROUP PLC (GB) | 1984-07-19 | — | — | WO | claimed |
| JP-61083176-A | — | — | None | — | — | JP | disclosed |
| US-12612395-B2 | Rocaglate derivatives and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260109721-A1 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON: SYNTHESIS AND LNP FORMULATION | ALDEXCHEM KFT (HU) | 2026-04-23 | — | — | US | disclosed |
| US-12534479-B2 | Triazine compound and composition and use thereof | FINDCURE BIOSCIENCES (ZHONGSHAN) CO., LTD. (CN) | 2026-01-27 | — | — | US | disclosed |
| US-20260008793-A1 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON | ALDEXCHEM KFT (HU) | 2026-01-08 | — | — | US | disclosed |
| EP-4646422-A1 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON: SYNTHESIS AND LNP FORMULATION | AldexChem Kft. (HU) | 2025-11-12 | — | — | EP | disclosed |
| EP-3448417-B1 | INSULIN DIMER-INCRETIN CONJUGATES | MERCK SHARP & DOHME LLC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250340557-A1 | PYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-06 | — | — | US | disclosed |
| EP-3660040-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4562021-A2 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON | AldexChem Kft. (HU) | 2025-06-04 | — | — | EP | disclosed |
| US-20250158123-A1 | NONAQUEOUS ELECTROLYTE FOR NONAQUEOUS-ELECTROLYTE CELL, AND NONAQUEOUS-ELECTROLYTE CELL | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2025-05-15 | — | — | US | disclosed |
| EP-4553068-A1 | PYRIMIDINE DERIVATIVES | ASKA Pharmaceutical Co., Ltd. (JP) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250115593-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025052296-A1 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON: SYNTHESIS AND LNP FORMULATION | ALDEXCHEM KFT. (HU) | 2025-03-13 | — | — | WO | disclosed |
| EP-4520765-A1 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON | AldexChem Kft. (HU) | 2025-03-12 | — | — | EP | disclosed |
| US-20250064992-A1 | IMAGING METHOD FOR DESIGNER RECEPTOR, ANTAGONIST OR AGONIST, PHARMACEUTICAL, AND COMPANION DIAGNOSTIC AGENT | NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) | 2025-02-27 | — | — | US | disclosed |
| CN-119285628-A | Compounds for the treatment and prophylaxis of respiratory syncytial virus infection diseases | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20250006995-A1 | CATHOLYTES FOR A SOLID-STATE BATTERY | QUANTUMSCAPE BATTERY, INC. | 2025-01-02 | — | — | US | disclosed |
| EP-3666792-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-4475256-A1 | NONAQUEOUS ELECTROLYTE FOR NONAQUEOUS-ELECTROLYTE CELL, AND NONAQUEOUS-ELECTROLYTE CELL | Panasonic Intellectual Property Management Co., Ltd. (JP) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024240062-A1 | PYRIDINE-PYRROLO DERIVATIVE AND USE THEREOF IN DRUGS | 广东东阳光药业股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| EP-4441811-A1 | CATHOLYTES FOR A SOLID-STATE BATTERY | QuantumScape Battery, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024193689-A1 | PYRIDINOPYRROLE DERIVATIVE AND USE THEREOF IN DRUGS | 广东东阳光药业股份有限公司 | 2024-09-26 | — | — | WO | disclosed |
| CN-118318325-A | Catholyte for solid state battery | 昆腾斯科普电池公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024137329-A1 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ALEXION PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240173311-A1 | METHODS AND COMPOSITIONS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-118076581-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240166679-A1 | USE OF KETOACIDS FOR LIGNIN STABILIZATION DURING EXTRACTION FROM LIGNOCELLULOSIC BIOMASS | LYGG CORPORATION | 2024-05-23 | — | — | US | disclosed |
| US-20240150385-A1 | Production of Fragments of Lignin with Functional Groups | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2024-05-09 | — | — | US | disclosed |
| WO-2024088343-A1 | ARYL HETEROCYCLIC KV1.3 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-05-02 | — | — | WO | disclosed |
| US-11967676-B2 | Catholytes for a solid-state battery | QUANTUMSCAPE BATTERY, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2024077078-A2 | STERYLGLUCOSIDASE INHIBITING COMPOSITIONS AND METHOD OF USING | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024023174-A2 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON | ALDEXCHEM KFT. (HU) | 2024-02-01 | — | — | WO | disclosed |
| CN-112494656-B | Insulin receptor partial agonists | 默沙东有限责任公司 | 2024-01-30 | — | — | CN | disclosed |
| WO-2024010015-A1 | PYRIMIDINE DERIVATIVES | あすか製薬株式会社 | 2024-01-11 | — | — | WO | disclosed |
| EP-4301831-A1 | USE OF KETOACIDS FOR LIGNIN STABILIZATION DURING EXTRACTION FROM LIGNOCELLULOSIC BIOMASS | LYGG Corporation (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20240002399-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-4291221-A1 | METHODS AND COMPOSITIONS FOR MODULATING FGF ACTIVITY | Recovery Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-220194438-U | Carbon dioxide trapping system with self-extraction layering function | 嘉兴市碳捕手科技有限责任公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11833210-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833210-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230330176-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2023-10-19 | — | — | US | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230327184-A1 | CATHOLYTES FOR A SOLID-STATE BATTERY | QUANTUMSCAPE BATTERY, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230279024-A1 | TRIAZINE COMPOUND AND COMPOSITION AND USE THEREOF | BEIJING FINDCURE BIOSCIENCES, LTD. (CN) | 2023-09-07 | — | — | US | disclosed |
| WO-2023145896-A1 | NONAQUEOUS ELECTROLYTE FOR NONAQUEOUS-ELECTROLYTE CELL, AND NONAQUEOUS-ELECTROLYTE CELL | パナソニックＩＰマネジメント株式会社 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023145896-A1 | NONAQUEOUS ELECTROLYTE FOR NONAQUEOUS-ELECTROLYTE CELL, AND NONAQUEOUS-ELECTROLYTE CELL | パナソニックＩＰマネジメント株式会社 | 2023-08-03 | — | — | WO | disclosed |
| EP-4219449-A2 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF PREPARATION THEREOF | Kura Oncology, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-114671829-B | Heterodiad taking indenone and dibenzoazepine as parent nucleus and hydrochloride thereof, preparation method and application thereof | 合肥工业大学 | 2023-07-25 | — | — | CN | disclosed |
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-116422109-A | Self-extraction layered carbon dioxide trapping system and method | 嘉兴市碳捕手科技有限责任公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023116748-A1 | SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | 广东东阳光药业有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121838-A1 | CATHOLYTES FOR A SOLID-STATE BATTERY | QUANTUMSCAPE BATTERY, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-4201941-A1 | PYRAZOLE BORONIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES THEREOF | Beijing Songrun Pharmaceutical Technology Co., Ltd. (CN) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023114200-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-4180433-A1 | TRIAZINE COMPOUND AND COMPOSITION AND USE THEREOF | Beijing Findcure Biosciences, Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| US-11633490-B2 | — | — | 2023-04-25 | — | — | US | disclosed |
| US-11634432-B2 | mTORC1 modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (CA) | 2023-04-25 | — | — | US | disclosed |
| EP-3660041-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2023051495-A1 | ISOQUINOLINONE AND QUINAZOLINONE COMPOUNDS, AND COMPOSITION AND USE THEREOF | 中山医诺维申新药研发有限公司 | 2023-04-06 | — | — | WO | disclosed |
| CN-115916755-A | Azetidine cyclic ureas | 维泰瑞隆有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20230101362-A1 | RNA STABILIZATION | TEAM MEDICAL LLC | 2023-03-30 | — | — | US | disclosed |
| CN-112920246-B | Method for synthesizing On-DNA1,4-thiazepine compound | 成都先导药物开发股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2023044455-A2 | RNA STABILIZATION | TEAM MEDICAL LLC (US) | 2023-03-23 | — | — | WO | disclosed |
| US-11603377-B2 | MTORC1 modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| WO-2023020486-A1 | RIP1 KINASE INHIBITOR COMPOUND AND COMPOSITION AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2023-02-23 | — | — | WO | disclosed |
| US-20230046569-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-02-16 | — | — | US | disclosed |
| EP-4126229-A1 | MTORC1 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115697991-A | Piperazine cyclic ureas | 维泰瑞隆有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115697972-A | Receptor-interacting protein 1 inhibitors comprising piperazine heterocyclic amide ureas | 维泰瑞隆有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11542248-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | KURA ONCOLOGY, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022247760-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR, AND PREPARATION THEREFOR AND USE THEREOF IN TREATMENT | 上海科州药物研发有限公司 | 2022-12-01 | — | — | WO | disclosed |
| CN-112409253-B | Method for synthesizing chiral alpha-tertiary amine by catalytic kinetic resolution | 上海科技大学 | 2022-11-29 | — | — | CN | disclosed |
| CN-110407769-B | 3, 4-dihydro-benzo [ f ] [1,4] thiazepine-5 (2H) -one compounds and pharmaceutical use thereof | 复旦大学 | 2022-11-08 | — | — | CN | disclosed |
| US-20220332727-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2022-10-20 | — | — | US | disclosed |
| US-11472779-B1 | One-pot synthesis of hydrogen-bonded organic frameworks | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2022-10-18 | — | — | US | disclosed |
| CN-110035994-B | Heterocyclic compound and harmful arthropod control composition containing same | 住友化学株式会社 | 2022-10-18 | — | — | CN | disclosed |
| WO-2022187716-A1 | USE OF KETOACIDS FOR LIGNIN STABILIZATION DURING EXTRACTION FROM LIGNOCELLULOSIC BIOMASS | LYGG CORPORATION (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4045513-A1 | PRODUCTION OF FRAGMENTS OF LIGNIN WITH FUNCTIONAL GROUPS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022174062-A1 | METHODS AND COMPOSITIONS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20220235069-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2022-07-28 | — | — | US | disclosed |
| CN-114671829-A | Heterodiad with indanone and dibenzoazepine as parent nucleus, hydrochloride thereof, preparation method and application thereof | 合肥工业大学 | 2022-06-28 | — | — | CN | disclosed |
| CN-114616265-A | Production of lignin fragments with functional groups | 洛桑联邦理工学院 | 2022-06-10 | — | — | CN | disclosed |
| EP-4006030-A2 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | Kura Oncology, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11324729-B2 | NSD family inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-05-10 | — | — | US | disclosed |
| EP-3454945-B1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | UNIV MICHIGAN REGENTS (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-109952300-B | 5-or 8-substituted imidazo [1,5-a ] pyridines | 百济神州有限公司 | 2022-01-18 | — | — | CN | disclosed |
| EP-3922260-A2 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | MERCK SHARP & DOHME CORP. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-11147885-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3303317-B1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | KURA ONCOLOGY INC (US) | 2021-10-06 | — | — | EP | disclosed |
| WO-2021195599-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20210275696-A1 | NOVEL COMPOUND BINDING TO DESIGNER RECEPTOR, IMAGING METHOD FOR DESIGNER RECEPTOR, AGONIST OR ANTAGONIST, THERAPEUTIC AGENT, COMPANION DIAGNOSTIC AGENT, AND IMAGING METHOD FOR NERVE CELL | NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) | 2021-09-09 | — | — | US | disclosed |
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-07 | — | — | US | disclosed |
| US-11058775-B2 | Insulin dimer-incretin conjugates | MERCK SHARP & DOHME CORP. (US) | 2021-07-13 | — | — | US | disclosed |
| CN-107531693-B | 5 or 8-substituted imidazo [1, 5-a ] pyridines as indoleamine, tryptophan dioxygenase inhibitors | 百济神州有限公司 | 2021-07-06 | — | — | CN | disclosed |
| WO-2021113669-A1 | CANNABINOIDS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| CN-112920246-A | Method for synthesizing On-DNA1, 4-thiazepine compound | 成都先导药物开发股份有限公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-106188099-B | 1, 4-thiazepine derivative and synthetic method thereof | 新乡医学院 | 2021-05-07 | — | — | CN | disclosed |
| CN-106188099-B | 1, 4-thiazepine derivative and synthetic method thereof | 新乡医学院 | 2021-05-07 | — | — | CN | disclosed |
| CN-106188099-B | 1, 4-thiazepine derivative and synthetic method thereof | 新乡医学院 | 2021-05-07 | — | — | CN | disclosed |
| EP-3812373-A1 | NOVEL COMPOUND BINDING TO DESIGNER RECEPTOR, IMAGING METHOD FOR DESIGNER RECEPTOR, AGONIST OR ANTAGONIST, THERAPEUTIC AGENT, COMPANION DIAGNOSTIC AGENT, AND IMAGING METHOD FOR NERVE CELL | NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) | 2021-04-28 | — | — | EP | disclosed |
| WO-2021074210-A1 | PRODUCTION OF FRAGMENTS OF LIGNIN WITH FUNCTIONAL GROUPS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-04-22 | — | — | WO | disclosed |
| EP-3808755-A1 | PRODUCTION OF FRAGMENTS OF LIGNIN WITH FUNCTIONAL GROUPS | Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-20210107917-A1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20210101908-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10953076-B2 | Insulin receptor partial agonists and GLP-1 analogues | MERCK SHARP & DOHME CORP. (US) | 2021-03-23 | — | — | US | disclosed |
| CN-112165940-A | OX2R compound | 德克萨斯州立大学董事会 | 2021-01-01 | — | — | CN | disclosed |
| US-20200330545-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2020-10-22 | — | — | US | disclosed |
| CN-111801334-A | Treatment of indolent or aggressive B-cell lymphomas using combinations comprising BTK inhibitors | 百济神州瑞士有限责任公司 | 2020-10-20 | — | — | CN | disclosed |
| US-10800827-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3221343-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10752639-B2 | Bridged bicyclic inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200246474-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2020-08-06 | — | — | US | disclosed |
| EP-3666792-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3660040-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3660041-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20200165224-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | WELLSPRING BIOSCIENCES LLC | 2020-05-28 | — | — | US | disclosed |
| CN-107207438-B | Bipyridine compound and use thereof for harmful arthropod control | 住友化学株式会社 | 2020-04-28 | — | — | CN | disclosed |
| US-10632209-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-04-28 | — | — | US | disclosed |
| CN-107501274-B | It can be used as the compound of ATR kinase inhibitor | Votex Pharmaceutical Co., Ltd. (US) | 2019-11-22 | — | — | CN | disclosed |
| CN-107501275-B | It can be used as the compound of ATR kinase inhibitor | Votex Pharmaceutical Co., Ltd. (US) | 2019-11-22 | — | — | CN | disclosed |
| US-10428082-B2 | Triazole derivatives of melampomagnolide B and methods of use thereof | BIOVENTURES, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-10344002-B2 | Compositions and methods for treating metabolic disorders | NUSIRT SCIENCES, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190192675-A1 | INSULIN DIMER-INCRETIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190183865-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-20 | — | — | US | disclosed |
| US-20190144442-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
| US-20190142906-A1 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190142799-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
| US-20190142961-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
| US-20190092833-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190092783-A1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190040077-A1 | TRIAZOLE DERIVATIVES OF MELAMPOMAGNOLIDE B AND METHODS OF USE THEREOF | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS | 2019-02-07 | — | — | US | disclosed |
| US-10183981-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME LLC | 2019-01-22 | — | — | US | disclosed |
| US-10174041-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | KURA ONCOLOGY, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| CN-106459033-B | Indoloquinolones as inhibitors of anaplastic lymphoma enzyme (A L K) | 江苏亚盛医药开发有限公司 | 2018-12-21 | — | — | CN | disclosed |
| US-20180291078-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-10-11 | — | — | US | disclosed |
| EP-2817315-B1 | SELECTIVE DETECTION OF THIOLS | THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIV (US) | 2018-09-19 | — | — | EP | disclosed |
| US-10017556-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2018106818-A1 | METHODS OF PROMOTING BETA CELL PROLIFERATION | KURA ONCOLOGY, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106820-A1 | METHODS OF PROMOTING BETA CELL PROLIFERATION | KURA ONCOLOGY, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| EP-3177600-B1 | SYNTHESIS OF BENZOTHIAZEPINES | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-05-23 | — | — | EP | disclosed |
| US-20180105531-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | WELLSPRING BIOSCIENCES LLC | 2018-04-19 | — | — | US | disclosed |
| US-20180105531-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | WELLSPRING BIOSCIENCES LLC | 2018-04-19 | — | — | US | disclosed |
| US-20180105498-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | NUSIRT SCIENCES, INC. | 2018-04-19 | — | — | US | disclosed |
| US-20180105498-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | NUSIRT SCIENCES, INC. | 2018-04-19 | — | — | US | disclosed |
| CN-107629059-A | It can be used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2018-01-26 | — | — | CN | disclosed |
| CN-107501274-A | It can be used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2017-12-22 | — | — | CN | disclosed |
| CN-107501275-A | It can be used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2017-12-22 | — | — | CN | disclosed |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834529-B2 | Synthesis of benzothiazepines | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| WO-2017197240-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017189342-A1 | INSULIN DIMER-INCRETIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2017-11-02 | — | — | WO | disclosed |
| CN-104903325-B | Compounds useful as inhibitors of ATR kinase | 沃泰克斯药物股份有限公司 | 2017-10-20 | — | — | CN | disclosed |
| WO-2017161002-A1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20170210717-A1 | SYNTHESIS OF BENZOTHIAZEPINES | GlaxSmithKline Intellectual Propety (No.2) Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| US-9709572-B2 | Fluorescence detection of cysteine and homocysteine | PORTLAND STATE UNIVERSITY (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170182115-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2017-06-29 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
| CN-104395311-B | Intermediates and processes for preparing compounds | 基因泰克公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-106459033-A | Indoloquinolones as anaplastic lymphoma enzyme (ALK) inhibitors | 江苏亚盛医药开发有限公司 | 2017-02-22 | — | — | CN | disclosed |
| WO-2016195776-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | KURA ONCOLOGY, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016197027-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | KURA ONCOLOGY, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-9506929-B2 | Selective detection of amino group containing thiols | PORTLAND STATE UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2563122-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2016-06-08 | — | — | EP | disclosed |
| EP-2637646-B1 | A PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2016-05-11 | — | — | EP | disclosed |
| US-9321787-B2 | Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-20160077103-A1 | FLUORESCENCE DETECTION OF CYSTEINE AND HOMOCYSTEINE | PORTLAND STATE UNIVERSITY (US) | 2016-03-17 | — | — | US | disclosed |
| US-9229007-B2 | Fluorescence detection of cysteine and homocysteine | PORTLAND STATE UNIVERSITY (US) | 2016-01-05 | — | — | US | disclosed |
| EP-2681210-B1 | 1,4 THIAZEPINES/SULFONES AS BACE1 AND/OR BACE2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | disclosed |
| WO-2015123453-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
| US-9040544-B2 | 2,5-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2015-05-26 | — | — | US | disclosed |
| US-9040518-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2015-05-26 | — | — | US | disclosed |
| CN-102753548-B | Fused heteroaromatic pyrrolidones as SYK inhibitors | TAKAEDA CHEMICAL IND LTD | 2015-03-11 | — | — | CN | disclosed |
| CN-104411311-A | Substituted benzamides and their use | UNIV LELAND STANFORD JUNIOR | 2015-03-11 | — | — | CN | disclosed |
| US-20150031637-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2015-01-29 | — | — | US | disclosed |
| CN-104321332-A | Compositions and methods of conjugating oligonucleotides | AGILENT TECHNOLOGIES INC | 2015-01-28 | — | — | CN | disclosed |
| US-20150010938-A1 | SELECTIVE DETECTION OF THIOLS | OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2015-01-08 | — | — | US | disclosed |
| EP-2817315-A1 | SELECTIVE DETECTION OF THIOLS | The Oregon State Board of Higher Education on Behalf of Portland State University (US) | 2014-12-31 | — | — | EP | disclosed |
| US-8907093-B2 | Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring | SANOFI (FR) | 2014-12-09 | — | — | US | disclosed |
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-8846690-B2 | Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846692-B2 | Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846691-B2 | Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20140206095-A1 | FLUORESCENCE DETECTION OF CYSTEINE AND HOMOCYSTEINE | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND ST (US) | 2014-07-24 | — | — | US | disclosed |
| US-8785439-B2 | 2,5,7-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8748436-B2 | Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8735387-B2 | Oxazolopyrimidines as Edg-1 receptor agonists | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| US-8735402-B2 | Cycloalkyloxycarboxylic acid derivatives | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| EP-2681210-A1 | 1,4 THIAZEPINES/SULFONES AS BACE1 AND/OR BACE2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8580816-B2 | Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| US-20130236541-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2013-09-12 | — | — | US | disclosed |
| WO-2013126816-A1 | SELECTIVE DETECTION OF THIOLS | OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2013-08-29 | — | — | WO | disclosed |
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20130158051-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20130137685-A1 | 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| EP-2583720-A1 | Oxazolopyrimidines as Edg-1 receptor agonists | SANOFI (FR) | 2013-04-24 | — | — | EP | disclosed |
| US-20130079357-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-03-28 | — | — | US | disclosed |
| US-20130079358-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-03-28 | — | — | US | disclosed |
| US-20130072502-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| EP-2318415-B1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI SA (FR) | 2013-02-20 | — | — | EP | disclosed |
| WO-2013019978-A1 | FLUORESCENCE DETECTION OF CYSTEINE AND HOMOCYSTEINE | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20130029938-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130023545-A1 | CYCLOALKYLOXYCARBOXYLIC ACID DERIVATIVES | SANOFI (FR) | 2013-01-24 | — | — | US | disclosed |
| US-20130023557-A1 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[5,4-B]PYRIDINE RING | SANOFI (FR) | 2013-01-24 | — | — | US | disclosed |
| US-20130023558-A1 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[4,5-c]PYRIDINE RING | SANOFI (FR) | 2013-01-24 | — | — | US | disclosed |
| US-20130023544-A1 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[5,4-d]PYRIMIDINE RING | SANOFI (FR) | 2013-01-24 | — | — | US | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| CN-102459258-A | Preparation and use of 1,2, 4-triazolo [1,5a ] pyridine derivatives | CEPHALON INC | 2012-05-16 | — | — | CN | disclosed |
| US-8178077-B2 | Drug development target protein and target gene, and method of screening | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178077-B2 | Drug development target protein and target gene, and method of screening | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20120076863-A1 | NANOPARTICULATE STABILIZED ANTI-HYPERTENSIVE COMPOSITIONS | ELAN PHARMA INTERNATIONAL LTD. | 2012-03-29 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| EP-1535913-B1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2011-11-02 | — | — | EP | disclosed |
| CN-102149712-A | Pyrazolo [3,4-b ] pyridine Raf inhibitors | ARRAY BIOPHARMA INC | 2011-08-10 | — | — | CN | disclosed |
| US-20110190490-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| CN-102015707-A | RAF inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC | 2011-04-13 | — | — | CN | disclosed |
| US-20110052648-A1 | ORAL MODIFIED-RELEASE FORMULATIONS CONTAINING THIAZEPINES | AVRAMOFF AVI | 2011-03-03 | — | — | US | disclosed |
| US-20110046101-A1 | BATE-LACTAMASE INHIBITORS | DMITRIENKO GARY I | 2011-02-24 | — | — | US | disclosed |
| EP-2268283-A2 | ORAL MODIFIED-RELEASE FORMULATIONS CONTAINING THIAZEPINES | Dexcel Ltd. (IL) | 2011-01-05 | — | — | EP | disclosed |
| EP-2255825-A2 | COMPOSITION FOR PREVENTING OR TREATING BRAIN DISEASES | Regeron, Inc. (KR) | 2010-12-01 | — | — | EP | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| EP-1485377-B9 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| EP-2174939-A1 | Pyranones useful as ATM inhibitors | Kudos Pharmaceuticals Limited (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100028439-A1 | Nanoparticulate stabilized anti-hypertensive compositions | ELAN PHARMA INTERNATIONAL LIMITED | 2010-02-04 | — | — | US | disclosed |
| EP-1485377-B1 | PYRANONES USEFUL AS ATM INHIBITORS | KUDOS PHARM LTD (GB) | 2009-12-09 | — | — | EP | disclosed |
| US-7626042-B2 | O-substituted hydroxyaryl derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| WO-2009114921-A1 | INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES | DMITRIENKO GARY I (CA) | 2009-09-24 | — | — | WO | disclosed |
| US-20090233274-A1 | DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING | REVERSE PROTEOMICS RESEARCH INSTITUTE CO. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233274-A1 | DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING | REVERSE PROTEOMICS RESEARCH INSTITUTE CO. (JP) | 2009-09-17 | — | — | US | disclosed |
| WO-2009113051-A2 | ORAL MODIFIED-RELEASE FORMULATIONS CONTAINING THIAZEPINES | DEXCEL LTD. (IL) | 2009-09-17 | — | — | WO | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| EP-1865962-A2 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | Arcadia Pharmaceuticals Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20070232582-A1 | 4-substituted or unsubtituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-7229983-B2 | 4-substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as β-lactamase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| WO-2006107948-A2 | USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060111409-A1 | Medicament for treatment of diabetes | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-25 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060089395-A1 | Nf-kb activation inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1649852-A1 | CHROMATOSIS REMEDIES | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20060035944-A1 | Remedies for neurodegenerative diseases | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-02-16 | — | — | US | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20060014811-A1 | Medicament for treatment of cancer | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| US-6942966-B1 | libraries formed by permutations; combinatorial chemistry; drug screening | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| US-6921760-B2 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1555018-A1 | REMEDIES FOR NEURODEGENERATIVE DISEASES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1173205-B1 | AN ORAL FORMULATION FOR ILEUM ADMINISTERING COMPRISING AN INHIBITOR COMPOUND OF THE ILEAL BILE ACID TRANSPORT | ASTRAZENECA AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20050101611-A1 | Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-6861419-B2 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-6861419-B2 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-6861419-B2 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| US-20040234619-A1 | Methods for remodeling neuronal and cardiovascular pathways | CELLEGY PHARMACEUTICALS, INC. | 2004-11-25 | — | — | US | disclosed |
| US-20040214812-A1 | 4-Substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2004-10-28 | — | — | US | disclosed |
| US-6787553-B2 | SEXUAL DISORDERS; VASODILATION | CELLEGY PHARMACEUTICALS, INC. | 2004-09-07 | — | — | US | disclosed |
| US-20040138291-A1 | Treatment of sexual dysfunction | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-07-15 | — | — | US | disclosed |
| US-20040063719-A1 | Combination therapy using antihypertensive agents and endothelin antagonists | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-04-01 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351692-A1 | ORAL FORMULATION COMPRISING AN INHIBITOR COMPOUND OF THE ILEAL BILE TRANSPORT AND AN HMG CO-A REDUCTASE INHIBITOR | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1324993-A2 | SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| EP-1324993-A2 | SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| US-6562813-B2 | Psychological disorders; antiserotonin agents; headache therapy | PFIZER INC. | 2003-05-13 | — | — | US | disclosed |
| US-6559303-B1 | Bridgehead atoms are bonded to one or more bridges that interconnect one or more ring systems thereby forming a large cyclic structure. Located in each bridge are two or more nitrogenous moieties that are derivatized with chemical | ISIS PHARMACEUTICALS, INC. | 2003-05-06 | — | — | US | disclosed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | disclosed |
| WO-2001079187-A8 | SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AND THEIR USE AS ACTIVATORS OF CASPASES | CYTOVIA INC (US) | 2003-02-20 | — | — | WO | disclosed |
| US-20030008020-A1 | Methods for remodeling neuronal and cardiovascular pathways | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-01-09 | — | — | US | disclosed |
| US-6472388-B2 | PSYCHOTHERAPEUTIC AGENTS. | PFIZER INC | 2002-10-29 | — | — | US | disclosed |
| US-20020147186-A1 | Crystalline dibenzothiazepine derivative and its use as an antipsychotic agent | ZENECA LIMITED | 2002-10-10 | — | — | US | disclosed |
| US-6458797-B1 | IN ILIO-HYPOGASTRIC-PUDENDAL ARTERIAL BED AND GENITALIA BY ADMINISTERING TO HUMANS THERAPEUTICALLY EFFECTIVE AMOUNT OF ANTI-PRESSOR AGENT | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2002-10-01 | — | — | US | disclosed |
| US-6423708-B1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC | 2002-07-23 | — | — | US | disclosed |
| US-6403592-B1 | SEROTONIN REUPTAKE INHIBITORS | PFIZER INC | 2002-06-11 | — | — | US | disclosed |
| US-6380186-B1 | PSYCHOTHERAPEUTIC AGENTS | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| WO-2002032428-A1 | ORAL FORMULATION COMPRISING AN INHIBITOR COMPOUND OF THE ILEAL BILE TRANSPORT AND AN HMG CO-A REDUCTASE INHIBITOR | ASTRAZENECA AB (SE) | 2002-04-25 | — | — | WO | disclosed |
| US-20020035067-A1 | Methods for remodeling neuronal and cardiovascular pathways | CELLEGY PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2001079187-A3 | SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AND THEIR USE AS ACTIVATORS OF CASPASES | CYTOVIA INC (US) | 2002-02-21 | — | — | WO | disclosed |
| US-20020022587-A1 | Methods for effecting neuroprotection | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-02-21 | — | — | US | disclosed |
| US-20020010169-A1 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | disclosed |
| US-20020010169-A1 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | disclosed |
| US-20020010169-A1 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | disclosed |
| EP-1173205-A1 | AN ORAL FORMULATION FOR ILEUM ADMINISTERING COMPRISING AN INHIBITOR COMPOUND OF THE ILEAL BILE ACID TRANSPORT | AstraZeneca AB (SE) | 2002-01-23 | — | — | EP | disclosed |
| US-6329523-B1 | FOR ANTIBACTERIAL PHARMACEUTICAL USE, USEFUL FOR IDENTIFYING METAL CHELATING SPECIES FOR ?HEAVY METAL? THERAPY; IMAGING AGENTS | ISIS PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| WO-2001079187-A2 | SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AND THEIR USE AS ACTIVATORS OF CASPASES | CYTOVIA, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001079187-A2 | SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AND THEIR USE AS ACTIVATORS OF CASPASES | CYTOVIA, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| US-6284763-B1 | ADMINISTERING LOW DOSAGE OF ANTIPRESSOR AGENT | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-09-04 | — | — | US | disclosed |
| US-6207826-B1 | Macrocyclic compounds having nitrogen-containing linkages | ISIS PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| US-6197965-B1 | POLYARYLALKYLAMINO-SUBSTITUED PYRIDINE DERIVATIVES; DRUGS, MEDICINE, DIAGNOSTICS | ISIS PHARMACEUTICALS, INC. | 2001-03-06 | — | — | US | disclosed |
| US-6191273-B1 | 3,6,10,14-SUBSTITUTED-3,6,10,16-TETRAAZABICYCLO(10.3.1)-HEXADE CA-1(16),12,14-TRIENE COMPOUNDS OF GIVEN FORMULA; ANTIBACTERIAL AND OTHER UTILITIES, SUCH AS TO SCREEN FOR PESTICIDES OR DRUGS | ISIS PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| US-6150571-A | Process for the preparation of 2,4-dichloro-3,5-dimethyl-fluorobenzene | BAYER AKTIENGESELLSCHAFT (DE) | 2000-11-21 | — | — | US | disclosed |
| WO-2000062810-A1 | AN ORAL FORMULATION FOR ILEUM ADMINISTERING COMPRISING AN INHIBITOR COMPOUND OF THE ILEAL BILE ACID TRANSPORT | ASTRAZENECA AB (SE) | 2000-10-26 | — | — | WO | disclosed |
| EP-0817787-A4 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2000-09-13 | — | — | EP | disclosed |
| US-6107482-A | LARGE CYCLIC STRUCTURES INTERRUPTED BY AT LEAST ONE RING SYSTEM WHICH INCLUDES TWO BRIDGEHEAD ATOMS; CONTAIN PLURALITY NITROGENOUS SITES THAT ARE DERIVATIZED SUCH AS WITH DRUGS, NUCLEIC ACIDS, PROTEINS; USE IN LIBRARIES | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-6077954-A | COMPOUNDS ARE CONSTRUCTED TO INCLUDE A CENTRAL AROMATIC, ALIPHATIC, OR HETEROCYCLIC RING SYSTEM. ATTACHED TO THE CENTRAL RING SYSTEM ARE TWO LINEAR GROUPS HAVING NITROGENOUS MOIETIES THAT ARE DERIVATIZED WITH CHEMICAL FUNCTIONAL GROUPS. | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-20 | — | — | US | disclosed |
| WO-1999011612-A2 | SUBSTITUTED CYCLIC COMPOUNDS AND MIXTURES COMPRISING SAME | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| US-5817652-A | ATHEROSCLEROSIS | GLAXO WELLCOME INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5817835-A | COCATALYSTS IN CHLORINATION OF TOLUENE | OCCIDENTAL CHEMICAL CORPORATION (US) | 1998-10-06 | — | — | US | disclosed |
| US-5814627-A | ANTIINFLAMMATORY AGENTS, ASTHMA; RHEUMATIC AND AUTOIMMUNE DISEASES; INHIBITORS OF LEUKOTRIENES, CYTOKINES, E.G. INTERLEUKINS, OXYGEN RADICALS AND PROTEASES | HOECHST AKTIENEGESELLSCHAFT (DE) | 1998-09-29 | — | — | US | disclosed |
| WO-1998010286-A1 | METHODS FOR PROCESSING CHEMICAL COMPOUNDS HAVING REACTIVE FUNCTIONAL GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-12 | — | — | WO | disclosed |
| US-5714603-A | 2,3-DIHYDRO-2,3-TETRAMETHYLENE-1,5-BENZO-1,4-THIOX-EPAN-5-ONE, OR -THIONE AND 2,3-DIHYDRO-2,3-TETRAMETHYLENE-1,6-BENZO-1,4,6-THIOXAZOCIN-5(6H)-ONE CO-CATALYSTS FOR PARA-DIRECTED RING CHLORINATION; CATALYST SELECTIVITY | OCCIDENTAL CHEMICAL CORPORATION (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0817787-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5703072-A | TREATMENT OF SCHIZOPHRENIA AND ANXIETY | ALLELIX BIOPHARMACEUTICALS (CA) | 1997-12-30 | — | — | US | disclosed |
| WO-1997047624-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1997-12-18 | — | — | WO | disclosed |
| WO-1997047625-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1997-12-18 | — | — | WO | disclosed |
| US-5684217-A | Process for preparing 3-fluoro-4,6-dichlorotoluene | BAYER AKTIENGESELLSCHAFT (DE) | 1997-11-04 | — | — | US | disclosed |
| US-5580866-A | Therapeutic 1,4-thiazepines | THE BOOTS COMPANY PLC (GB) | 1996-12-03 | — | — | US | disclosed |
| WO-1996030377-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0356006-B1 | Cyclic sulfur-containing compounds | SANTEN PHARMACEUTICAL CO LTD (JP) | 1994-03-02 | — | — | EP | disclosed |
| EP-0240366-B1 | Perhydrothiazepine and perhydroazepine derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1994-01-26 | — | — | EP | disclosed |
| US-5273989-A | 3,5-disubstituted 2-isoxazolines and isoxazoles, agents containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-12-28 | — | — | US | disclosed |
| EP-0365045-B1 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1993-12-01 | — | — | EP | disclosed |
| EP-0249610-B1 | SYNTHESIS OF OPTICALLY ACTIVE ARYLOXYPROPANOLAMINES AND ARYLETHANOLAMINES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-08-25 | — | — | EP | disclosed |
| CN-1021226-C | PREPARATION FOR ACYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 1993-06-16 | — | — | CN | disclosed |
| US-5206233-A | Antidepressants, antiischemic agents | WARNER-LAMBERT COMPANY (US) | 1993-04-27 | — | — | US | disclosed |
| US-5128467-A | Immunomodulation, liver disorders | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1992-07-07 | — | — | US | disclosed |
| US-5082836-A | Autoimmune diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1992-01-21 | — | — | US | disclosed |
| US-5041435-A | Treatment of Liver Disorders and Autoimmune Diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1991-08-20 | — | — | US | disclosed |
| US-4990707-A | Process for the ring chlorination of aromatic hydrocarbons | BAYER AKTIENGESELLSCHAFT (DE) | 1991-02-05 | — | — | US | disclosed |
| US-4990668-A | Reacting selected dioxolane with hydrohalic acid and organic acid, then with amine | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-02-05 | — | — | US | disclosed |
| EP-0161801-B1 | PERHYDROTHIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANKYO COMPANY LIMITED (JP) | 1990-11-07 | — | — | EP | disclosed |
| US-4923873-A | ANTIARRHYTHMIA AGENTS; SIDE EFFECT REDUCTION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-05-08 | — | — | US | disclosed |
| EP-0365045-A1 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1990-04-25 | — | — | EP | disclosed |
| EP-0356006-A1 | Cyclic sulfur-containing compounds | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
| EP-0248879-A4 | SYNTHESIS OF ARYLOXYPROPANOLAMINES AND ARYLETHANOLAMINES. | DU PONT (US) | 1990-02-26 | — | — | EP | disclosed |
| EP-0249610-A4 | SYNTHESIS OF OPTICALLY ACTIVE ARYLOXYPROPANOLAMINES AND ARYLETHANOLAMINES. | DU PONT (US) | 1990-02-21 | — | — | EP | disclosed |
| US-4778790-A | HYPOTENSIVE AGENTS | SANKYO COMPANY LIMITED (JP) | 1988-10-18 | — | — | US | disclosed |
| US-4755527-A | Aryl substituted aminomethyl benzene derivatives | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-07-05 | — | — | US | disclosed |
| US-4748184-A | Aryl substituted aminomethyl benzene derivatives having antiarrhythmic utility | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-05-31 | — | — | US | disclosed |
| EP-0249610-A1 | SYNTHESIS OF OPTICALLY ACTIVE ARYLOXYPROPANOLAMINES AND ARYLETHANOLAMINES. | DU PONT (US) | 1987-12-23 | — | — | EP | disclosed |
| EP-0248879-A1 | SYNTHESIS OF ARYLOXYPROPANOLAMINES AND ARYLETHANOLAMINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-12-16 | — | — | EP | disclosed |
| US-4699905-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1987-10-13 | — | — | US | disclosed |
| EP-0240366-A2 | Perhydrothiazepine and perhydroazepine derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1987-10-07 | — | — | EP | disclosed |
| WO-1987003584-A1 | SYNTHESIS OF OPTICALLY ACTIVE ARYLOXYPROPANOLAMINES AND ARYLETHANOLAMINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-06-18 | — | — | WO | disclosed |
| WO-1987003583-A1 | SYNTHESIS OF ARYLOXYPROPANOLAMINES AND ARYLETHANOLAMINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-06-18 | — | — | WO | disclosed |
| JP-S6183176-A | 1,4-THIAZEPINE DERIVATIVE, ITS PREPARATION AND PLANT DISEASE-COMBATING AGENT CONTAINING SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD | 1986-04-26 | — | — | JP | disclosed |
| US-4562201-A | ANTIARRHYTHMIA AGNETS | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1985-12-31 | — | — | US | disclosed |
| EP-0161801-A2 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1985-11-21 | — | — | EP | disclosed |
| EP-0113778-A4 | ARYL SUBSTITUTED AMINOMETHYL BENZENE DERIVATIVES USEFUL AS ANTIARRHYTHMIC AGENTS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1985-06-06 | — | — | EP | disclosed |
| EP-0068173-B1 | PERHYDRO-1,4-THIAZEPIN-5-ONE AND PERHYDRO-1,4-THIAZOCIN-5-ONE DERIVATIVES, PROCESS FOR PREPARING AND PHARMCEUTICAL COMPOSITION CONTAINING THE SAME | MERCK & CO. INC. (US) | 1984-09-26 | — | — | EP | disclosed |
| EP-0113778-A1 | ARYL SUBSTITUTED AMINOMETHYL BENZENE DERIVATIVES USEFUL AS ANTIARRHYTHMIC AGENTS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1984-07-25 | — | — | EP | disclosed |
| WO-1984000545-A1 | ARYL SUBSTITUTED AMINOMETHYL BENZENE DERIVATIVES USEFUL AS ANTIARRHYTHMIC AGENTS | AMERICAN HOSPITAL SUPPLY CORP (US) | 1984-02-16 | — | — | WO | disclosed |
| US-4251444-A | Thiazepino-[4,3-b]-isoquinoline-1,5-dione derivatives and precursors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
| US-4054572-A | Hexahydro pyridine [1,2d] dibenza [b,f] (1,4)-diazepines | AKZONA INCORPORATED (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054572-A | Hexahydro pyridine [1,2d] dibenza [b,f] (1,4)-diazepines | AKZONA INCORPORATED (US) | 1977-10-18 | — | — | US | disclosed |